Targeted therapies in advanced and metastatic urothelial carcinoma Review
| Authors: | Katims, A. B.; Reisz, P. A.; Nogueira, L.; Truong, H.; Lenis, A. T.; Pietzak, E. J.; Kim, K.; Coleman, J. A. |
| Review Title: | Targeted therapies in advanced and metastatic urothelial carcinoma |
| Abstract: | This review describes the current landscape of targeted therapies in urothelial carcinoma. The standard of care for advanced urothelial carcinoma patients remains platinum-based combination chemotherapy followed by immunotherapy. However, median overall survival for these patients is still <1 year and there is an urgent need for alternative therapies. The advent of next-generation sequencing has allowed widespread comprehensive molecular characterization of urothelial tumors and, subsequently, the development of therapies targeting specific molecular pathways implicated in carcinogenesis such as FGFR inhibition, Nectin-4, Trop-2, and HER2 targeting. As these therapies are demonstrated to be effective in the second-line setting, they will be advanced in the treatment paradigm to localized and even non-muscle invasive disease. © 2022 by the authors. |
| Keywords: | monoclonal antibodies; immunotherapy; metastatic urothelial carcinoma; molecular targeted therapy; tumor biomarkers; antineoplastic therapy; antibody-drug conjugates; next-generation sequencing |
| Journal Title: | Cancers |
| Volume: | 14 |
| Issue: | 21 |
| ISSN: | 2072-6694 |
| Publisher: | MDPI |
| Date Published: | 2022-11-01 |
| Start Page: | 5431 |
| Language: | English |
| DOI: | 10.3390/cancers14215431 |
| PROVIDER: | scopus |
| PMCID: | PMC9655342 |
| PUBMED: | 36358849 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 December 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work